Navigation Links
Possible hepatitis C vaccine
Date:9/5/2007

Hepatitis C Virus (HCV) infects up to 500,000 people in the UK alone, many of the infections going undiagnosed. It is the single biggest cause of people requiring a liver transplant in Britain. Now, in a collaborative effort with groups across Europe and the USA, scientists from The University of Nottingham have found monoclonal antibodies which may be a significant step towards a vaccine.

Hepatitis C treatment is expensive and not successful in all patients. Untreated or unresponsive patients can go on to develop cirrhosis of the liver, with life affecting consequences or the need for a liver transplant.

Dr Alexander Tarr, a Research Fellow at the Institute of Infection, Immunity and Inflammation presented a paper Human antibodies to Hepatitis C virus potential for vaccine design at the Society for General Microbiologys 161st meeting which is being held at The University of Edinburgh this week.

The group has recently analysed antibodies that can successfully prevent infection with many diverse strains of Hepatitis C virus in laboratory models. Dr Tarr said: The clinical potential of this work cannot be overstated. Historically, successful vaccines against viruses have required the production of antibodies, and this is likely to be the case for Hepatitis C virus. Identifying regions of the virus that are able to induce broadly reactive neutralising antibodies is a significant milestone in the development of a HCV vaccine, which will have distinct healthcare benefits for hepatitis sufferers, and could also help us design vaccines for other chronic viral diseases such as HIV.

Hepatitis C virus infects 180 million people worldwide. Infection with the virus can lead to liver cancer, and is the most common reason for liver transplantation in both the UK and the USA.

We are also currently exploring the possibility of improving liver transplantation success rates by passively infusing people with these antibodies said Dr Tarr. We are also using the information gained by identifying and characterising the antibody responses to Hepatitis C virus to design new ways of making vaccine candidates. If the antibodies we have discovered can be reproduced by vaccination, control of the disease might be possible.


'/>"/>

Contact: Dr. Alexander Tarr
alex.tarr@nottingham.ac.uk
University of Nottingham
Source:Eurekalert

Related biology news :

1. Viral DNA sequence a possible trigger for breast cancer
2. New studies suggest airborne SARS transmission is possible
3. New method shows it is possible to grow bone for grafts within a patients body
4. Stem Cells Found In Cerebellum; Possible Cell of Origin for Childhood Brain Tumors
5. Possible treatment found for chemobrain
6. Protein amplification in melanoma is possible drug target
7. Is it Possible to Change Prescribing Habits?
8. From one cell, many possible cures
9. Group proves its possible to grow new lung alveoli by growing new blood vessels
10. Oh, rats! Designer animals reveal possible heart disease genes
11. Team discovers possible universal strategy to combat addiction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell , ... technology, and STMicroelectronics (NYSE: STM), a global ... electronics applications, announced today the launch of a ... biometric wearables that includes ST,s compact SensorTile ... Benchmark™ biometric sensor system. Together, SensorTile and ...
(Date:12/16/2016)... , Dec 16, 2016 Research and ... System Market - Global Forecast to 2021" report to their ... The ... to grow at a CAGR of 14.06% from 2016 to 2021. ... and is projected to reach 854.8 Million by 2021. The growth ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... ... January 24, 2017 , ... ... PRM, a chronic disease and transitions of care solution for use by healthcare ... to work at the top of their license. Care teams, care managers ...
(Date:1/24/2017)... DURHAM, N.C. , Jan. 24, 2017 ... service and technology, announces that Daniel Eisenman , ... Biosafety Officer. In his new role, ... and manage a forthcoming institutional biosafety committee (IBC) service. ... navigating the IBC landscape. The new IBC service represents ...
(Date:1/24/2017)... 2017 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) ... to increase the size of the offering by 75% and ... with warrants to purchase 1,842,106 shares of common stock of ... of common stock (the "Exercise Price"), at a price to ... "Public Price"). The warrants have a term of four (4) ...
(Date:1/24/2017)... USA & Geneva, Switerland (PRWEB) , ... January ... ... to announce the first commercially available malaria Plasmodium falciparum culture panels with standard ... falciparum culture panels, which are available in a range of concentrations from six ...
Breaking Biology Technology: